Pfizer, Sanofi, Bristol Myers Squibb, Gilead’s Kite, Lilly’s Dermira, Janssen and Biogen among the major companies announcing transactions this week.

The company has assembled small molecule discovery capabilities for the development of targeted cancer drugs that it believes rivals big pharma efforts and will fulfill patients’ unmet needs.

European Probiotics specialist Probi has acquired a stake in US supplements firm Vital Nutrients, in a deal which will see the companies collaborate on new product development. 

Novartis passed up the chance for further development of Kyorin's mocravimod for autoimmune diseases but newly formed Priothera is evaluating the S1P receptor modulator for acute myeloid leukemia patients undergoing hematopoietic stem cell transplantation.